CJC1295 10 mg Longacting GHRH Analog

Key Benefits of CJC-1295 Pulsatile and Sustained GH Stimulation Through the DAC (Drug Affinity Complex) mechanism, CJC-1295 binds to serum albumin, extending its half-life to 5-8 days and providing GH release that mimics physiological pulses, preventing receptor desensitization and maintaining an optimal anabolic environment. A pivotal clinical trial demonstrated a 2 to 10-fold increase in mean GH levels for at least 6 days post-administration, with a favorable safety profile across all tested doses. This sustained release allows for continuous GH/IGF-1 axis stimulation without the abrupt peaks and troughs associated with other formulations, resulting in greater anabolic efficacy and lower incidence of side effects related to hormonal dysregulation. Significant IGF-1 Increase Sustained GH elevation leads to a parallel increase in hepatic and peripheral IGF-1, the primary effector of GH's anabolic actions. In the clinical trial, IGF-1 levels increased 1.5 to 3-fold above baseline, remaining elevated for 9-11 days. This sustained IGF-1 increase potentiates protein synthesis, cell proliferation, tissue differentiation, and amino acid uptake by skeletal muscle, creating an optimal environment for muscle growth and tissue repair. IGF-1 elevation also exerts neuroprotective effects and modulates synaptic function, contributing to improved cognitive function and neuronal plasticity. Improved Body Composition (Lean Mass and Fat Loss) GH exerts a potent lipolytic effect by stimulating hormone-sensitive lipase (HSL) and inhibiting lipoprotein lipase (LPL), promoting fatty acid oxidation and triglyceride mobilization from adipose tissue. Concurrently, GH and IGF-1 stimulate amino acid uptake and muscle protein synthesis through activation of the mTOR signaling pathway, favoring lean mass gain and visceral fat loss. This dual effect (anabolic and lipolytic) makes CJC-1295 an exceptional research tool for studies on body composition, energy metabolism, and metabolic syndrome, with potential applications in obesity, sarcopenia, and aging-associated metabolic disorders. Accelerated Muscle and Joint Recovery GH and IGF-1 are critical regulators of connective tissue repair. They promote fibroblast proliferation, collagen type I and III synthesis, and chondrocyte differentiation, accelerating recovery from injuries in muscles, tendons, and ligaments. GH also stimulates the release of growth factors such as FGF (Fibroblast Growth Factor) and VEGF (Vascular Endothelial Growth Factor), which promote angiogenesis and improve oxygen and nutrient supply to damaged tissues, accelerating the repair process. This is key for high-performance athletes, bodybuilders, and active individuals dealing with overuse injuries, acute trauma, or the wear and tear of intense training. Improved Sleep Quality and Cognitive Recovery GH is predominantly released during slow-wave sleep (phases III and IV of NREM sleep). By increasing endogenous GH levels, CJC-1295 can promote greater sleep depth, increasing time in these restorative stages and reducing nocturnal awakenings, leading to improved physical recovery, memory consolidation, executive function, and mood. GH also influences circadian rhythm regulation and melatonin secretion, contributing to better sleep-wake cycle synchronization and higher quality of nocturnal rest, which is fundamental for cognitive and physical performance. Reduced Downtime and Increased Training Frequency Accelerated recovery capacity and improved sleep quality allow research subjects to undergo more intense and frequent training cycles, with lower risk of overtraining and injury. GH promotes the repair of muscle micro-tears and the elimination of metabolic waste products such as lactic acid, accelerating post-workout recovery and allowing greater gym productivity. This translates to faster progression towards performance goals, better training adaptation, and lower incidence of overuse injuries, optimizing the benefit-risk ratio in research protocols. Optimized Mood and Overall Well-being GH and IGF-1 have neuroprotective effects and modulate neurotransmitter function such as serotonin, dopamine, and norepinephrine. Elevated GH levels have been correlated with improved mood, reduced fatigue, greater sense of overall well-being, and lower incidence of depressive and anxious symptoms. GH also influences synaptic plasticity and hippocampal neurogenesis, contributing to better cognitive function and greater resilience to stress. These psychoactive effects make CJC-1295 a promising research tool for studies on neuroendocrinology, psychopharmacology, and mood disorders, with potential applications in depression, anxiety, and sleep disorders.

Function and Mechanism of Action of CJC-1295 CJC-1295 is an analog of Growth Hormone-Releasing Hormone (GHRH), designed to stimulate GH secretion in a prolonged and physiological manner, respecting the body's endocrine feedback mechanisms. Its molecular structure incorporates a modification that allows it to covalently bind to 4-maleimidopropionic acid, forming the Drug Affinity Complex (DAC). This complex binds to serum albumin (the most abundant protein in blood plasma), protecting the peptide from proteolytic degradation by enzymes such as trypsin and chymotrypsin, and extending its elimination half-life to approximately 5-8 days, in contrast to the minutes or hours of half-life of other peptides such as GHRP-6 or Ipamorelin. Detailed Mechanism of Action: Albumin Binding (DAC): Following subcutaneous or intramuscular administration, CJC-1295 reversibly binds to serum albumin, forming a depot that slowly releases the active peptide. This binding reduces renal clearance rate and protects the peptide from enzymatic degradation, allowing sustained and controlled GH release. The half-life of albumin-bound CJC-1295 is 5-8 days, enabling administration 1-2 times per week, thus optimizing adherence to the research protocol. GHRH Receptor Stimulation: Active CJC-1295 binds to the GHRH receptor (GHRH-R) on the membrane of somatotroph cells in the anterior pituitary. This binding activates the cAMP/PKA (protein kinase A) signaling pathway, which in turn stimulates GH gene transcription, synthesis, and release into systemic circulation. This pathway is specific and does not interfere with other hormonal axes, minimizing unwanted side effects. Pulsatile and Physiological GH Secretion: Stimulation through GHRH-R produces GH pulses that mimic natural secretion, maintaining the negative feedback of the hypothalamic-pituitary axis. This avoids receptor desensitization and GH suppression, as can occur with exogenous GH administration or with agents that stimulate GH in a non-physiological manner. Pulsatile secretion is essential for maintaining target tissue sensitivity to GH and for avoiding insulin resistance and other adverse metabolic effects. IGF-1 Increase: Secreted GH acts on the liver and peripheral tissues, stimulating the production of IGF-1 (Insulin-like Growth Factor type 1), the main mediator of GH's anabolic actions. IGF-1 promotes cell proliferation, protein synthesis, and tissue differentiation through activation of the PI3K/Akt signaling pathway and inhibition of apoptosis. IGF-1 elevation also exerts neuroprotective effects and modulates synaptic function, contributing to improved cognitive function and neuronal plasticity. Lipolytic and Antilipogenic Effect: GH exerts a direct effect on adipose tissue, stimulating lipolysis through activation of hormone-sensitive lipase (HSL) and inhibiting lipogenesis by reducing the expression of lipoprotein lipase (LPL) and malic enzyme. This leads to decreased fat mass and increased fatty acid oxidation, improving metabolic efficiency and body composition. Promotion of Tissue Repair: GH and IGF-1 are mitogens and differentiation factors. They promote fibroblast proliferation, collagen type I and III synthesis, and new cell formation, accelerating repair of damaged tissues and muscle regeneration. GH also stimulates the release of growth factors such as FGF (Fibroblast Growth Factor) and VEGF (Vascular Endothelial Growth Factor), which promote angiogenesis and improve oxygen and nutrient supply to repairing tissues, accelerating the healing process and reducing downtime. Immune System Modulation: GH exerts immunomodulatory effects, stimulating T-cell production and macrophage activity, which may contribute to better immune response and lower incidence of infections in subjects undergoing intense training cycles. This effect is particularly relevant in contexts of physical and psychological stress, where the immune system may be compromised.

How to Use CJC-1295 Route of Administration: Injectable via subcutaneous (SC) or intramuscular (IM). For systemic effect and sustained release, subcutaneous administration is recommended, as it allows for more gradual and constant absorption, optimizing the GH release profile through the DAC mechanism. Injection sites should be rotated (abdomen, thigh, gluteal region) to avoid lipohypertrophy, fibrosis, and local irritation, ensuring uniform absorption and lower incidence of local complications. Reconstitution: The product is presented as a lyophilized powder in a sterile vial. It must be reconstituted with bacteriostatic water for injection (or sterile water for injection) before use. Add the diluent slowly, gently swirling the vial to dissolve the powder. Do not shake vigorously, as this can denature the peptide and reduce its biological activity. Once reconstituted, the vial should be visually inspected to ensure the solution is clear and particle-free. The reconstituted solution should be colorless or slightly yellowish, depending on concentration. Research Protocol: Dosage and frequency must be determined by the researcher according to protocol goals. Common research protocols for CJC-1295 (with DAC) use doses of 1-2 mg per administration, administered 1-2 times per week, to maintain elevated GH and IGF-1 levels. Research cycles of 8-12 weeks are recommended to assess changes in body composition, tissue recovery, sleep quality, and physical performance. For protocols combining CJC-1295 with GHRP-6, simultaneous administration (in the same syringe) or within a 10-15 minute interval is recommended, to leverage the synergistic effect and amplify the resulting GH peak. Storage: The lyophilized powder should be stored in a cool, dry place, protected from light and at controlled temperature (2-8°C), preferably in the refrigerator. Do not freeze the lyophilized powder, as this can damage the peptide structure and reduce its biological activity. Once reconstituted, it must be refrigerated (2-8°C) and used within 30 days to maintain peptide stability and prevent bacterial contamination. Freezing of the reconstituted solution is not recommended, as it can cause formation of protein aggregates and loss of activity. Safety Measures: Before administration, ensure the reconstituted solution is clear and free of particles. Use strict aseptic techniques to avoid contamination of the vial and solution. Discard any unused solution after 30 days of reconstitution. Do not mix with other peptides or medications in the same syringe unless compatibility and stability of the mixture have been established. Important Notice: Product intended EXCLUSIVELY FOR SCIENTIFIC RESEARCH in vitro and in animal models. Not approved for human, veterinary, or therapeutic use. The dosages and protocols mentioned are examples for research and do not constitute medical advice. The researcher is solely responsible for safety and compliance with applicable regulations during the development of the research protocol.

Ingredients of CJC-1295 Active Ingredient: CJC-1295 (GHRH Analog with DAC): A synthetic 30-amino acid peptide (sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-NH2) containing a covalent bond with 4-maleimidopropionic acid for the formation of the drug affinity complex (DAC). It is responsible for albumin binding and GHRH receptor stimulation, triggering GH release and subsequent IGF-1 elevation. The active ingredient purity is ≥99% by HPLC-MS, guaranteeing maximum reproducibility in research studies. Excipients: Mannitol: A sugar alcohol (polyol) that acts as a cryoprotectant and bulking agent, used to stabilize the peptide structure during the lyophilization process, preventing aggregation and loss of biological activity. Mannitol forms an amorphous matrix that protects the peptide from mechanical and thermal stresses during lyophilization and storage, ensuring structural integrity and biological activity of the product. Water for Injection (WfI): High-purity water (USP/EP grade) used as a vehicle in the lyophilization process to create the sterile powder. Water for injection undergoes a rigorous purification process including reverse osmosis, distillation, and sterile filtration to remove impurities, bacterial endotoxins, and particles, ensuring maximum purity of the final product. Note for Researchers: This product is a high-purity synthetic peptide (>99% by HPLC-MS), manufactured without unnecessary additives, preservatives, or fillers. Its production is carried out under strict quality control standards (GMP - Good Manufacturing Practices) to ensure maximum reproducibility in research studies. The absence of bacterial endotoxins (≤1 EU/mg), research-grade purity, and complete batch traceability ensure reliable and comparable results across different experiments. The product is pyrogen-free and manufactured in ISO 9001 and ISO 13485 certified facilities, guaranteeing the highest quality and safety standards for scientific research.

Onset Time & Expected Results of CJC-1295 For researchers seeking to understand timelines and reported changes in the literature, clinical and preclinical evidence suggests the following progression for CJC-1295, based on pharmacokinetic and pharmacodynamic studies in humans and animal models: Onset of Action (Hours to Days): Pharmacodynamic effects begin almost immediately after administration, with a detectable GH peak within the first 2-4 hours post-injection. GH reaches maximum concentrations between 4 and 6 hours after administration, remaining elevated for several hours. However, the sustained elevation of IGF-1, which is the key effector of many of GH's anabolic actions, may take several days to peak. The clinical study by Teichman et al. (2006) reported a significant increase in IGF-1 levels at 7-14 days post-administration, remaining elevated for 9-11 days after a single injection. Measurable Benefits (2-4 Weeks): Improvement in sleep quality, reduced fatigue, and perception of faster recovery are typically the first observable effects, reported by study participants within the first 2-4 weeks of treatment. Lipolysis and reduction in waist circumference begin to be noticeable in this period, along with improved mood and greater sense of overall well-being. Research subjects also report greater capacity to perform high-intensity training without experiencing excessive fatigue or overtraining. Full Effect (8-12 Weeks): For changes in body composition (increased lean mass and fat loss), and for significant tissue recovery, the full therapeutic effect often requires 8-12 weeks of consistent use according to the research protocol. Preclinical literature suggests that tendon and ligament recovery is optimized in this time frame, with significant improvement in joint strength and functionality. Studies in animal models have demonstrated that CJC-1295 administration for 8-12 weeks produces significant increase in muscle mass, reduction of visceral fat, and improvement in physical performance, with positive effects on bone density and cardiovascular function. Factors Influencing Results: The speed and magnitude of results depend on various factors, including dose administered, injection frequency, subject's nutritional status (especially protein and amino acid intake, as well as caloric balance), age, physical activity level, sex, genetics, and adherence to the research protocol. A caloric deficit can potentiate the lipolytic effect of GH, while a caloric surplus with adequate protein intake will potentiate the anabolic effect on muscle mass. Age also influences response to GH, with younger subjects typically showing more robust response due to greater target tissue sensitivity. Recommendations for Evaluation: For accurate evaluation of results, it is recommended to perform baseline and periodic measurements of body composition (via DEXA, bioimpedance, or anthropometry), muscle strength (dynamometry), physical performance (endurance and power tests), and sleep quality (polysomnography or validated questionnaires). Analysis of biochemical markers (GH, IGF-1, glucose, insulin, lipid profile) is also crucial for monitoring pharmacodynamic response and adjusting the research protocol accordingly.

Clinical Research & 3rd Party Test Results of CJC-1295 Scientific evidence on CJC-1295 is robust and supported by human clinical trials, unlike many other research peptides that lack robust clinical data. Up to 2026, studies have established its pharmacokinetic profile, its efficacy in elevating the GH/IGF-1 axis, and its safety in healthy populations. A systematic review of the literature confirms its role as a potent long-acting GH secretagogue, with a favorable benefit-risk ratio compared to exogenous GH administration. Clinical Evidence in Humans: Phase 1 Trial (Teichman et al., 2006, Journal of Clinical Endocrinology & Metabolism): In a double-blind, placebo-controlled study, a single subcutaneous injection of CJC-1295 (30, 60, or 125 µg/kg) in healthy men (n=42) increased mean GH concentrations by 2 to 10-fold for 6 days or more. IGF-1 increased 1.5 to 3-fold above baseline for 9-11 days. No significant adverse effects were observed, and tolerability was excellent across all tested doses. The study demonstrated that CJC-1295 is a potent, effective, and well-tolerated GH secretagogue, with a pharmacokinetic profile enabling weekly administration. Pharmacokinetic Properties: The study demonstrated an elimination half-life of approximately 5-8 days, with bioavailability of 87-95% for subcutaneous administration. The half-life of albumin-bound CJC-1295 is 6.5 ± 2.2 days, confirming its long-acting profile. Maximum GH concentration is reached between 4 and 6 hours post-administration, with systemic exposure (AUC) correlating positively with administered dose. Preclinical Studies: In animal models (rats and dogs), CJC-1295 has demonstrated dose-dependent GH release stimulation, with significant increase in muscle mass and reduction in body fat. Toxicology studies have demonstrated a favorable safety profile, with a maximum tolerated dose of 500 µg/kg in repeated administration. No serious adverse effects were observed in target organs (liver, kidney, heart), and hematological and biochemical parameters remained within normal limits. Ongoing Clinical Trials: Clinical trials are currently underway to evaluate the therapeutic potential of CJC-1295 in conditions such as obesity, sarcopenia, adult GH deficiency, and sleep disorders. A recent study has investigated its use in combination with GHRP-6 to potentiate GH release in patients with GH deficiency, showing promising results in normalizing IGF-1 levels and improving body composition and quality of life. Regulatory Status: CJC-1295 is not FDA-approved for any human, veterinary, or therapeutic use. It is classified as an investigational agent and is prohibited by the World Anti-Doping Agency (WADA) under category S2 (Peptide hormones, growth factors, and related substances). Its use is restricted exclusively to in vitro and animal model scientific research. Syntex Labs Quality Standards: Lab Grade: Purity ≥99% by HPLC-MS with Certificate of Analysis (COA) including purity, identity, bacterial endotoxin content, and sterility. QR Tracking: Complete batch traceability with access to production process information, quality control, and expiration dates. Secure Batch Label: "Scratch to See" security system to guarantee product authenticity and prevent counterfeiting. 3rd Party Results: Access to Certificates of Analysis (COA) from accredited external laboratories (ISO/IEC 17025) verifying product purity and identity. Each batch undergoes quality control testing by an independent laboratory to ensure maximum transparency and reliability. Stability Testing: Real-time and accelerated stability studies (according to ICH Q1A) confirming product stability for 24 months under recommended storage conditions.